• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

FIT members – Who works on WHAT?

Roles of ALL FIT Members

UPDATED on 3/25/2020

OUR Board of Advisors:

TBD from a pool of External Relations

OUR Board Members:

  • Prof. Marcus W. Feldman
  • Stephen J Williams 

OUR Founder:

  • Aviva Lev-Ari, PhD, RN

OUR Scientists are:

  • Jason Zielonka, MD, AFACC
  • Justin D. Pearlman, MD/PhD, FACC
  • Stephen J. Williams, PhD 
  • Irina Robu, PhD
  • Sudipta Saha, PhD
  • Ofer Markman, PhD

OUR Business Team include:

  • Gail – Marketing Communications
  • Rick – Business Development & Marketing: Digital Published Products
  • Joel Shertok, PhD – Business Development of a Global bot-based Prospecting Cloud-based System

External Affiliations and ex-LPBI

  • Medical Doctors: Dr. Larry H. Bernstein (retired), Dr. Pearlman (Central Maine Medical Center), Jason Zielonka, MD, AFACC
  • Doctors of Philosophy: Dr. Pearlman, Dr. Williams, Dr. Saha, Dr. Saxena, Dr. Barliya, Dr. Robu, Dr. Nir, Dr. Lev-Ari,, Joel Shertok
  • Professors in Academia: Prof. Marcus W. Feldman (Stanford University), Prof. Stephen J. Williams (Temple University), Prof. Sudipta Saha (Amity University Noida, Uttar Pradesh, India), Dr. Irina Robu (Windsor, Ontario, Canada), Adam Sonnenberg, PhD(c), Boston University
  • Executives in the biotechnology industry: Gail S. Thornton (Merck USA), Ritu Saxena (Astellas Pharma)
  • Executives in high tech industries: Rick Mandahl

FIT members – Who works on WHAT?

UPDATED on 3/25/2020

Project 1: Coronavirus Portal Project 2: 2020 BUZ_PLN Project 3 Project 4 Project 5
OUR Board Members
Prof. Marcus W. Feldman, PhD Content FEEDER Re-Architect of BUZ_PLN No repetitions Assist in finding an acquirer among Academic Publishers Assist in contacting Coursera Assist in identification of Advisory board members
Prof. Stephen J Williams, PhD see, below Comments on 4/1/2020 see, below see, below see, below
OUR Founder
Aviva Lev-Ari, PhD, RN LAUNCHER AND An Epidemiological Approach AND Diagnosis of Coronavirus Infection by Medical Imaging AND KOLs Document preparation Prospecting in person for Acquirers NLP, ML, AI on Journal Articles e-Book and     e-Proceedings Formalization of Asset Classes Artifacts
OUR Science TEAM
Jason Zielonka, MD, AFACC Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus Comments on 4/1/2020 See Roles @LPBI on CV See Roles @LPBI on CV See Roles @LPBI on CV
Justin D. Pearlman, MD/PhD, FACC Diagnosis of Coronavirus Infection by Medical Imaging Comments on 4/1/2020 WEEKLY One NEW POST UPDATE own Posts UPDATE Larry’s Posts
Stephen J. Williams, PhD An Epidemiological Approach AND Community IMPACT Comments on 4/1/2020 WEEKLY One NEW POST UPDATE own Posts UPDATE Larry’s Posts
Irina Robu, PhD Community IMPACT Comments on 4/1/2020 WEEKLY One NEW POST UPDATE own Posts UPDATE Larry’s Posts
Sudipta Saha, PhD Voices of Global Citizens Comments on 4/1/2020 WEEKLY One NEW POST UPDATE own Posts UPDATE Larry’s Posts
Ofer Markman, PhD Key Opinion Leaders Followed by LPBI Comments on 4/1/2020 Relationship Development: LPBI and Israel Biotech Manage relations Noam Ordan and Summer Interns Relationship Development: Investors in Israel
OUR Business Team
Gail – Marketing Communications Voices of Global Citizens Comments on 4/1/2020 Newsletter e-VOICES – Podcast Library Series Customer Surveys
Rick Mandahl – Business Development & Marketing: Digital Published Products Voices of Global Citizens Comments on 4/1/2020 and Contact the IB SelectHealth Crain Communications Self Initiated
Joel Shertok, PhD – Business Development of a Global bot-based Prospecting Cloud-based System Economic Impact Document Preparation BOT System on Aviva’s LinkedIn connections BOT systmes on JayZ’s LinkedIn connections BOT systems on Joel’s LinkedIn connections

UPDATED on 3/25/2019

 

Scientists Tasks for ALL FIT MEMBERS – UPDATED on 3/24/2019

·       UPDATE their CV on the Journal

[Completion on 5/15/2019]

·       New Posts per Commissions to keep Journal ALIVE

[Ongoing, EACH SCIENTIST needs to initiate NEW posts and posy per Commissions]

·       Attend Skypes with FIT members

[Sessions are 2 hours long]

·       Attend Skypes with Investment Banker, as needed

·       Retweet for

·       @AVIVA1950

·       @pharma_BI

·       IMPLEMENT GAIL’s Tips for Twitter.com

[Ongoing]

 FIT Member’s Progress Report – self documented inside Scientist’s cell Aviva provides

1.      Feedbacks and

2.      Defines and Assigns new tasks as needed for Request For Information (RFI) by Investment Banker (IB)
Dr. Pearlman IP Valuation Model for Intangibles – work with Aviva

[Concept implementation Will start in May 2019]

Please Skype with Aviva ASAP
Dr. Williams 1. Update last 10 articles of SJW & LHB

[Progress report DUE]

2. Reconnect to Social Media

[Ongoing]

3. New Posts per Commissions

[Ongoing]

4. Review and comments on Section #13

[Progress report DUE]

____________________
Dr. Barliya 1. Update last 10 articles of TB & LHB’s 10 before last 10

[Progress report DUE]

2. Reconnect to Social Media of own past posts

[Progress report DUE]

3. New Posts per Commissions

[Ongoing]

_________________
Dr. Robu 1. Weekly Articles Update per list from Aviva

[Progress report DUE]

2. Update last 10 articles of Irina & LHB 20   to 30 lasts

[Progress report DUE]

3. New Posts per Commissions

[Ongoing]

____________________
Dr. Nir 1. Update last 10 articles of Dror Nir

[Progress report DUE]

2. New Posts per Commissions

[Ongoing]

___________________
Dr. Saxena 1. SumAll

[Not addressed yet]

2. Collapse Categories

[Ongoing]

3. Valuation Model of the Journal, Scoring each Article

[Not addressed yet]

_______________
Dr. Saha 1. Update last 10 articles of S. Saha

[Progress report DUE]

2. Reconnect to Social Media

[Ongoing]

3. New Posts per Commissions

[Ongoing]

_________________
Aviva 1. Forecasting Model per e-Series

2. BioMed eReaders behavior on Amazon – 16 Files

3. Architecture of Positioning Model – to send to IB

4. IP Valuation Model for Intangibles – work with Dr. Pearlman

5. Tweeter Filtering @pharma_Bi for Total Followers’ Followers

6. Identifying Most Honored to be followed by for Tweets by ALL FIT members

7. Sending IB intermediate results

8. Schedule Skype sessions with FIT Members

9. Schedule Skype sessions with IB

10. Schedule Skype sessions with business tycoons in Global markets

_______________
Prof. Marc Feldman – Member of the Board 1. Review Aviva’s Final Reports for editorial and comments [Ongoing]

2. Advice per RFI

[Ongoing]

3. Attend Meetings with IB

[To be Scheduled]

4. Attend selective meetings with FIT Members per topic

[To be Scheduled]

_________________
Bus DEV & Marketing Digital Published Products
Rick 1. Competitive Space of LPBI [submitted to Aviva’s satisfaction]

2. Market Plan for +60 Biotech e-Proceedings

[PENDING]

3. Journal Subscribers List from WordPress

[PENDING]

4. Identify markets for eSeries

[PENDING]

________________
AMNON ·       Tweeter  IMPLEMENT GAIL’s Tips

@pharma_BI @AVIVA1950

[PENDING]

·       LinkedIn

Aviva’s 1st level Connections in Biotech/Pharma & Publishing and VC – Global

[PENDING]

2. Aviva’s 1st level Connections in Biotech/Pharma and VC – Israel

[PENDING]

_____________
GAIL

Marketing Communication

 

 

 
Document #2 with Aviva

[Ongoing]

LPBI Group’s Marketing Communications

Gail’s Progress Report on Assigned Tasks, 4/14/2019:

  • May 3 podcast (with Aviva, Stephen, Irina) arranged with Partners in Health and Biz (40,000 circulation)
  • Handling several requests from outside writers to post on LPBI site
  • Revised key messages (see March 27 email to you)
  • Received estimate of LPBI newsletter on developing specialty newsletters per conference
  • Sent email to Aviva to approve general tweet/narrow tweet (see March 28 email to you)
  • Updating existing articles that Gail has developed to LPBI site
  • Provided LPBI pipeline write up (see March 18 email to you)
  • Provided 1/2-page writeup on media (see March 28 email to you).

 

 

Original Created on March 4, 2019

Scientists Tasks for ALL FIT MEMBERS

·       UPDATE their CV on the Journal

·       New Posts per Commissions to keep Journal ALIVE

·       Attend Skypes with FIT members

·       Attend Skypes with Investment Banker, as needed

·       Retweet for

·       @AVIVA1950

·       @pharma_BI

·       IMPLEMENT GAIL’s Tips

 

 FIT Member’s Progress Report – self documented inside Scientist’s cell Aviva provides

1.      Feedbacks and

2.      Defines and Assigns new tasks as needed for Request For Information (RFI) by Investment Banker (IB)
Dr. Pearlman IP Valuation Model for Intangibles – work with Aviva

 
Dr. Williams 1. Update last 10 articles of SJW & LHB

2. Reconnect to Social Media

3. New Posts per Commissions
Dr. Barliya 1. Update last 10 articles of TB & LHB’s 10 before last 10

2. Reconnect to Social Media

3. New Posts per Commissions
Dr. Robu 1. Weekly Articles Update per list from Aviva

2. Update last 10 articles of Irina & LHB 20   to 30 lasts

3. New Posts per Commissions
Dr. Nir 1. Update last 10 articles of Dror Nir

2. New Posts per Commissions
Dr. Saxena 1. SumAll

2. Collapse Categories

3. Valuation Model of the Journal, Scoring each Article
Dr. Saha 1. Update last 10 articles of S. Saha

2. Reconnect to Social Media

3. New Posts per Commissions
Aviva 1. Forecasting Model per e-Series

2. BioMed eReaders behavior on Amazon – 16 Files

3. Architecture of Positioning Model – to send to IB

4. IP Valuation Model for Intangibles – work with Dr. Pearlman

5. Tweeter Filtering @pharma_Bi for Total Followers’ Followers

6. Identifying Most Honored to be followed by for Tweets by ALL FIT members

7. Sending IB intermediate results

8. Schedule Skype sessions with FIT Members

9. Schedule Skype sessions with IB

10. Schedule Skype sessions with business tycoons in Global markets
Prof. Marc Feldman – Member of the Board 1. Review Aviva’s Final Reports for editorial and comments

2. Advice per RFI

3. Attend Meetings with IB

4. Attend selective meetings with FIT Members per topic
Bus DEV & Marketing Communication
Rick 1. Competitive Space of LPBI

2. Market Plan for +60 Biotech e-Proceedings

3. Journal Subscribers List from WordPress

4. Identify markets for eSeries
Amnon ·       Tweeter – IMPLEMENT GAIL’s Tips

@pharma_BI @AVIVA1950

·       LinkedIn

1. Aviva’s 1st level Connections in Biotech and VC – Global

2. Aviva’s 1st level Connections in Biotech and VC – Israel
GAIL

Marketing Communication

 

 

 
Positioning Document with Aviva

 

Roles of ALL FIT Members

OUR Board Members:

  • Larry – Medical Leave
  • Feldman

OUR Scientists are:

  • Justin
  • Williams
  • Tilda
  • Irina
  • Dror Nir
  • Ritu
  • Saha
  • Adam [2019 – MD/PhD since LPBI days (2015), Completed format conversion in 2015 for 7 e-Books]

OUR Business Team include:

  • Gail – Marketing Communications
  • Amnon – Strategy
  • Rick – Marketing

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,001 other subscribers

  • Recent Posts

    • Clarivate Analytics – a Powerhouse in IP assets and in Pharmaceuticals Informercials September 15, 2022
    • Near Term Investment Outlook for 2023: A Perspective from Advisors Potentially Affecting M&A Landscape August 5, 2022
    • SOP for production of WordClouds for articles in the NEW GENRE Audio English-Spanish: BioMed e-Series – 18 Volumes in Medicine July 25, 2022
    • Cardiothoracic surgeons at UC San Francisco performed the first robotically assisted mitral valve prolapse surgery in San Francisco. July 22, 2022
    • Explanation on “Results of Medical Text Analysis with Natural Language Processing (NLP) presented in LPBI Group’s NEW GENRE Edition: NLP” on Genomics content, standalone volume in Series B and NLP on Cancer content as Part B New Genre Volume 1 in Series C   July 7, 2022
    • Sperm damage and fertility problem due to COVID-19 June 23, 2022
    • Genomic data can predict miscarriage and IVF failure June 15, 2022
    • The Human Genome Gets Fully Sequenced: A Simplistic Take on Century Long Effort June 14, 2022
    • Aortic Valve Transplant Via Carotid Artery at Hadassah – An Israel First May 29, 2022
    • Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF May 23, 2022

  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 Rosalind Codrington, PhD
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


%d bloggers like this: